drugset / Trial / NCT00432276

Efficacy of Alogliptin and Pioglitazone in Subjects With Type 2 Diabetes Mellitus

NCT00432276

Phase 3 Completed 803 enrolled Takeda
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of the study is to compare the effect of adding alogliptin, once daily (QD), to the ongoing treatment regimen of pioglitazone HCl and metformin in patients with inadequate glycemic control.

Timeline

Start
2007-01
Primary completion
2009-05
Completion
2009-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Alogliptin Unknown 25 mg Oral
Subject Pioglitazone Small molecule 30 mg Oral
Subject Pioglitazone Small molecule 45 mg Oral
Background Metformin Small molecule 1500 mg Oral